Atom Investors’s Adaptive Biotechnologies ADPT Stock Holding History

Atom Investors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,991	Closed	-$389K	–	562
2025 Q3	$389K	Buy	+25,991	New	+$317K	0.03%	400
2024 Q3	–	Sell	-10,954	Closed	-$39.7K	–	462
2024 Q2	$39.7K	Sell	10,954 -55,010	-83%	-$175K	﹤0.01%	448
2024 Q1	$212K	Buy	+65,964	New	+$255K	0.03%	477
2021 Q3	–	Sell	-28,761	Closed	-$1.18M	–	304
2021 Q2	$1.18M	Sell	28,761 -22,140	-43%	-$861K	0.15%	112
2021 Q1	$2.05M	Buy	+50,901	New	+$2.76M	0.34%	66
2019 Q3	–	Sell	-20,000	Closed	-$966K	–	277
2019 Q2	$966K	Buy	+20,000	New	+$886K	0.06%	258

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Atom Investors's ADPT Position: Q4 2025 in Review

Atom Investors sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 25,991 shares — an estimated $389K sold.

Atom Investors first reported a position in ADPT in Q2 2019 and held it in 6 quarters. The position peaked at $2.05M in Q1 2021. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

Atom Investors reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
Atom Investors sold 25,991 Adaptive Biotechnologies shares in Q4 2025, an estimated $389K.
Atom Investors first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 6 quarters.
Atom Investors's Adaptive Biotechnologies position peaked at $2.05M in Q1 2021.
283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.